Sorafenib is a single-agent MTI developed by Onyx and Bayer’s that targets VEGFR, PDGFR, c-Kit, and rapidly accelerated fibrosarcoma (Raf) for the treatment of RCC and HCC [38,39]. The gene discussed is KIT; the disease is renal cell carcinoma.